Dennis W Lambert

US Patent:

6020459, Feb 1, 2000

Filed:

Jun 7, 1995

Appl. No.:

8/484223

Inventors:

Shawn O'Lin Barney - Cary NC
Dennis Michael Lambert - Cary NC
Stephen Robert Petteway - Cary NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

A61K 3800
A61K 3921

US Classification:

530300

Abstract:

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1. sub. LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

US Patent:

6348568, Feb 19, 2002

Filed:

May 20, 1999

Appl. No.:

09/315304

Inventors:

Shawn Barney - Apex NC
Kelly I. Guthrie - Graham NC
Gene Merutka - Saratoga CA
Mohmed K. Anwer - Foster City CA
Dennis M. Lambert - Cary NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

C07K 200

US Classification:

530300, 530324, 530328, 530350, 530351, 530397, 530399

Abstract:

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

US Patent:

6440656, Aug 27, 2002

Filed:

Jun 7, 1994

Appl. No.:

08/255208

Inventors:

Dani Paul Bolognesi - Durham NC
Thomas James Matthews - Durham NC
Carl T. Wild - Durham NC
Shawn OLin Barney - Cary NC
Dennis Michael Lambert - Cary NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

C12Q 170

US Classification:

435 5, 435 71, 530300, 530324, 530325, 530326, 4242111

Abstract:

Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C. A. S. T. ) that detects related structural motifs (e. g. , ALLMOTI5, 107Ã178Ã4, and PLZIP) in other viral proteins was employed to identify similar regions in the respiratory syncytial virus (RSV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the RSV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of RSV fusion.

US Patent:

6479055, Nov 12, 2002

Filed:

Jun 6, 1995

Appl. No.:

08/470896

Inventors:

Dani Paul Bolognesi - Durham NC
Thomas James Matthews - Durham NC
Carl T. Wild - Durham NC
Shawn OLin Barney - Cary NC
Dennis Michael Lambert - Cary NC
Stephen Robert Petteway - Cary NC
Alphonse J. Langlois - Durham NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

A61K 39145

US Classification:

4242111, 4241861, 530324

Abstract:

The present invention relates to peptides which exhibit potent anti-viral activity. In particular, the invention relates to methods of using such peptides as inhibitory of respiratory syncytial virus (âRSVâ) transmission to uninfected cells. The peptides used in the methods of the invention are homologs of the DP-178 and DP-107 peptides, peptides corresponding to amino acid residues 638 to 673, and to amino acid residues 558 to 595, respectively, of the HIV-1 transmembrane protein (TM) gp41.

US Patent:

6518013, Feb 11, 2003

Filed:

Jun 7, 1995

Appl. No.:

08/485546

Inventors:

Shawn OLin Barney - Cary NC
Dennis Michael Lambert - Cary NC
Stephen Robert Petteway - Cary NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

C12Q 170

US Classification:

435 5, 4242301, 530300, 530324, 530325, 530326

Abstract:

Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1(HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C. A. S. T. ) that detects related structural motifs (e. g. , ALLMOTI 5, 107Ã178Ã4, and PLZIP) in other viral proteins was employed to identify similar regions in the Epstein-Barr virus (EBV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the EBV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of EBV fusion.

US Patent:

6562787, May 13, 2003

Filed:

Apr 13, 2001

Appl. No.:

09/834784

Inventors:

Shawn Barney - Apex NC
Kelly I. Guthrie - Graham NC
Gene Merutka - Hillsborough NC
Mohmed K. Anwer - Foster City CA
Dennis M. Lambert - Cary NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

A61K 3816

US Classification:

514 12, 514 2

Abstract:

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

US Patent:

6623741, Sep 23, 2003

Filed:

Feb 29, 2000

Appl. No.:

09/515965

Inventors:

James B. Antczak - Durham NC
Mary K. Delmedico - Raleigh NC
Joel B. Erickson - Durham NC
Dennis M. Lambert - Durham NC
Prakash Sista - Durham NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

A61K 39155

US Classification:

4242111, 530324

Abstract:

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention are derived from regions of viral fusion proteins referred to as HR1 and HR2. In particular, the invention relates to peptides referred to herein as DP107 and DP178 which comprise amino acid sequences corresponding to sequences found in the HR1 and HR2 regions, respectively of the HIV-1 gp41 protein. The invention further relates to âDP107-likeâ and âDP178-likeâ peptides that are derived from HR1 and HR2 regions, respectively, of other proteins, including DP107-like and DP178-like peptides derived from the HR1 and HR2 regions of the F1 subunit of the respiratory syncytial virus fusion protein.

US Patent:

6656906, Dec 2, 2003

Filed:

Jul 9, 1999

Appl. No.:

09/350641

Inventors:

Shawn Barney - Apex NC
Kelly I. Guthrie - Virginia Beach VA
Gene Merutka - Saratoga CA
Mohmed K. Anwer - Foster City CA
Dennis M. Lambert - Cary NC

Assignee:

Trimeris, Inc. - Durham NC

International Classification:

A61K 3816

US Classification:

514 12, 514 2, 514 13, 514 15, 530300, 530324, 530326, 530328, 530350

Abstract:

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.